How Cigna’s AI chief is investing in the technology to cut costs and address some of healthcare’s biggest problems

Before we get to this week’s column—Please consider joining us at the inaugural Fortune AIQ Summit at the New York Stock Exchange on Oct.

1: Spend the afternoon with senior executives from companies on the Fortune AIQ 75 list and explore how you can scale your AI experimentation and translate investments into measurable business value.

Apply here to attend .

After Katya Andresen joined Cigna Group as chief data, digital and AI officer in September 2021, she says the emergence of generative artificial intelligence as a disruptive new technology led many to ask themselves: “How do I use AI?” Andresen thinks that’s the wrong question.

“We’ve been on a mission to change that question to, ‘how do I lead in an age of AI?’” says Andresen.

That framing is less focused on the functionality of any given AI tool and chasing countless use cases, and instead homes in on measurement that shows an AI investment can change health outcomes.

Along those lines, Cigna has announced this summer that it projects the AI and predictive analytics tools that the company uses to help patients identify chronic conditions—including cancer, kidney disease, and high-risk pregnancy—can save an estimated $200 million over the next three years by proactively connecting patients with clinicians.

Separately this summer, Cigna announced a $100 million investment through 2028 to use AI to reduce the time clinicians need to spend documenting their cases and speed up the prescription process.

And yet another AI use case, which Andresen shared with Fortune , involves using AI to better understand common inbound patient questions that Cigna was receiving about biosimilars, which can treat chronic diseases at a fraction of the cost of biologics.

Unlike a generic drug, which has the same active ingredients as branded counterparts, biosimilars aren’t an exact match because they’re made from living organisms like bacteria and plant cells.

But both are approved by the Food and Drug Administration.

One biologic, called Humira, can cost a patient $7,000 per month to treat inflammatory and autoimmune conditions.

But Cigna looked at thousands of prior customer conversations with its representatives about biologics and biosimilars, and then used those insights to craft stronger digital messaging to encourage a switch to the cheaper alternative.

This targeted campaign led more than 80% to opt for the biosimilar, Andresen says.